5432452026-08-095432452026-08-09in-capmkt:ArrangementsForStrategicOrTechnicalOrManufacturingOrMarketingTieUpMemberGLANDGLAND PHARMA LIMITED543245NOTLISTEDINE068V01023Arrangement/Adoption of new line/Closure of operations (Sub-para 2-Para B)Arrangements for strategic, technical, manufacturing, or marketing tie upNewfalse2026-08-0901:20:002026-08-09AgreementGlobal Pharmaceutical Company [Name cannot be disclosed due to confidentiality obligations]A Strategic Manufacturing and Supply Agreement (MSA) for the Technology Transfer, Manufacturing and Supply of a portfolio of sterile injectable products for global markets. The product portfolio comprises a diversified basket of oncology and non-oncology products in vial, Lyo, Ampoules and pre-filled syringe (PFS) presentations, covering both complex and conventional injectable formulations. Under the agreement, Gland Pharma will leverage its integrated capabilities across development, technology transfer, manufacturing, quality and regulatory support to provide a comprehensive "one-stop" solution to its partner.InternationalNot ApplicableFull-service CDMO model encompassing technology transfer, process development, scale-up, validation, commercial manufacturing, and long-term supply of sterile injectable products.The agreement is expected to provide strong long-term business visibility, with revenue generation anticipated from calendar year 2029. The current agreement covers 55 SKUs to be manufactured across three sites, with scope of adding more products soon. Once all products are commercialized, the annualized revenue potential is expected to be approximately USD 90–100 million.Full-service CDMO model encompassing technology transfer, process development, scale-up, validation, commercial manufacturing, and long-term supply of sterile injectable products.falseCannot be disclosed due to confidentiality obligationsThe agreement is expected to provide strong long-term business visibility, with revenue generation anticipated from calendar year 2029. The current agreement covers 55 SKUs to be manufactured across three sites, with scope of adding more products soon. Once all products are commercialized, the annualized revenue potential is expected to be approximately USD 90–100 million.